Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Revance Therapeutics (RVNC) Financial Statements
569 Followers
Revance Therapeutics Financial Overview
| Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Income Statement | - | ||||
| Total Revenue | $ 69.80M | $ 56.78M | $ 58.13M | $ 49.33M | $ 49.92M |
| Gross Profit | $ 52.33M | $ 37.36M | $ 36.83M | $ 49.33M | $ 57.25M |
| EBIT | - | $ -131.95M | $ -59.54M | $ -55.30M | $ -143.71M |
| EBITDA | - | $ -131.16M | $ -56.94M | $ -53.29M | $ -127.46M |
| Net Income Common Stockholders | $ -55.70M | $ -141.18M | $ -67.32M | $ -59.79M | $ -145.95M |
| Balance Sheet | - | ||||
| Cash, Cash Equivalents and Short-Term Investments | $ 253.91M | $ 300.25M | $ 320.00M | $ 274.22M | $ 340.71M |
| Total Assets | $ 478.45M | $ 532.49M | $ 597.53M | $ 547.80M | $ 581.90M |
| Total Debt | $ 478.43M | $ 487.90M | $ 432.39M | $ 435.72M | $ 418.47M |
| Net Debt | $ 224.52M | $ 187.65M | $ 112.39M | $ 161.49M | $ 77.76M |
| Total Liabilities | $ 630.06M | $ 638.69M | $ 570.75M | $ 574.47M | $ 569.30M |
| Stockholders Equity | $ -151.60M | $ -106.20M | $ 26.79M | $ -26.67M | $ 12.60M |
| Cash Flow | - | ||||
| Free Cash Flow | - | $ -55.47M | $ -53.10M | $ -70.38M | $ -31.47M |
| Operating Cash Flow | $ -42.73M | $ -50.96M | $ -53.36M | $ -69.51M | $ -30.18M |
| Investing Cash Flow | $ 2.37M | $ 51.59M | $ -39.53M | $ 95.32M | $ 40.96M |
| Financing Cash Flow | $ -1.63M | $ 37.46M | $ 97.47M | $ 3.27M | $ -6.17M |